The HHS Office for Civil Rights said it is investigating a "major" health system in Michigan that may have fired an employee for refusing to use a patient's preferred pronouns—meaning, those that align with gender identity rather than biological sex. The agency contends that such compelled speech may violate federal laws protecting religious freedom.
ACR joined 10 medical societies filing a “friend of the court” brief in an ongoing lawsuit against the National Institutes of Health, HHS and their leaders.
The group highlighted the proven effectiveness of these drugs, especially semaglutide and tirzepatide, while noting that eligibility, affordability and availability will still play key roles in any treatment decisions.
Workforce solutions could include regional on-call pools serving multiple facilities and cross-training vascular surgeons and interventional cardiologists on select procedures.
RSNA and several other industry societies have shared a new expert consensus document on the significant value of cardiac CT. Echo remains an effective first-line imaging option, the groups wrote, but CT can make a big impact as well.
Gregory R. Ball, MD, filed the complaint against Southtowns Radiology Associates in February, and the practice is now asking a judge to reject his allegations.
Experts believe this new research offers important insights as practices adopt artificial intelligence in breast imaging, often with an extra out-of-pocket fee.
BlackSuit has “significant similarities” to the Royal ransomware family, a direct successor of the “notorious” Russian-linked Conti operation, the agency reported.
The HHS Office for Civil Rights said it is investigating a "major" health system in Michigan that may have fired an employee for refusing to use a patient's preferred pronouns—meaning, those that align with gender identity rather than biological sex. The agency contends that such compelled speech may violate federal laws protecting religious freedom.
ACR joined 10 medical societies filing a “friend of the court” brief in an ongoing lawsuit against the National Institutes of Health, HHS and their leaders.
The group highlighted the proven effectiveness of these drugs, especially semaglutide and tirzepatide, while noting that eligibility, affordability and availability will still play key roles in any treatment decisions.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/stack_views/public/2024-09/istock-1209664264.jpg.webp?itok=MzQCOefT)
